Search

Displaying results 971 - 980 of 6076 in total
  1. Drug

    Prademagene zamikeracel

    go.drugbank.com/drugs/DB17895
    ApprovedInvestigational

    [L53008] COL7A1 encodes type VII collagen (C7), which is a major component of anchoring fibrils (AF) that are critical for dermal-epidermal cohesion. … [L53008] Prademagene zamikeracel was first approved by the FDA on April 29, 2025, for the treatment of recessive dystrophic epidermolysis bullosa (RDEB), a skin disorder associated with excessive blistering

  2. Drug

    Osilodrostat

    go.drugbank.com/drugs/DB11837
    ApprovedInvestigational

    [A191850] Osilodrostat was approved for use in the EU in January 2020 for the treatment of endogenous Cushing's syndrome (i.e. … [A191910] As an orally bioavailable drug therapy, osilodrostat provides a novel treatment option for patients in whom removal of the causative tumor is not an option or for whom previous pituitary surgery

  3. Drug

    Echothiophate

    go.drugbank.com/drugs/DB01057
    ApprovedInvestigational

    Occasionally used for accomodative esotropia.

  4. Drug

    Ebastine

    go.drugbank.com/drugs/DB11742
    ApprovedInvestigationalWithdrawn

    Ebastine is under investigation for the treatment of Irritable Bowel Syndrome (IBS). Ebastine has been investigated for the treatment of Urticaria.

    Categories: Antihistamines for Systemic Use
  5. Drug

    Ethambutol

    go.drugbank.com/drugs/DB00330
    ApprovedInvestigational

    [A229048] It was developed out of a need for therapies active against isoniazid resistant strains of _Mycobacterium tuberculosis_.[A229048] Ethambutol was granted FDA approval on 6 November 1967.

    Categories: Antiinfectives for Systemic Use, Drugs for Treatment of Tuberculosis
  6. Drug

    Drotaverine

    go.drugbank.com/drugs/DB06751
    ApprovedWithdrawn

    It is approved for use in Thailand as oral tablets or intramuscular injections.[L22689]

    Categories: Drugs for Functional Gastrointestinal Disorders
  7. Drug

    Carbon monoxide

    go.drugbank.com/drugs/DB11588
    ApprovedInvestigational

    The ten seconds of breath-holding required for the DLCO maneuver is easier for most patients to perform than the forced exhalation required for other respiratory tests [L2557]. … The DLCO test is both convenient and simple for the patient to undergo.

  8. Drug

    Ribavirin

    go.drugbank.com/drugs/DB00811
    ApprovedInvestigational

    It is primarily indicated for use in treating hepatitis C and viral hemorrhagic fevers. … According to 2017 American Association for the Study of Liver Diseases (AASLD) and 2015 consensus guidelines from the Canadian Association for the Study of the Liver (CASL), ribavirin is typically used

    Categories: Antivirals for Systemic Use, Antiinfectives for Systemic Use
  9. Drug

    Ruxolitinib

    go.drugbank.com/drugs/DB08877
    ApprovedInvestigational

    [L39125] It is being investigated for other inflammatory skin conditions. … [A229708] In 2014, it was approved for the treatment of polycythemia vera in adults who have an inadequate response to or are intolerant of [hydroxyurea] and in 2019, ruxolitinib was approved for use in

    Categories: Agents for Dermatitis, Excluding Corticosteroids
  10. Drug

    Lasmiditan

    go.drugbank.com/drugs/DB11732
    ApprovedInvestigational

    suitable for use in patients with pre-existing cardiovascular disorders. … [A187316,A187322] Lasmiditan, in contrast, is a highly selective agonist of 5-HT<sub>1F</sub> receptors, carrying virtually no affinity for other receptors which appear to be largely responsible for